Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Genetics Generation Advancement EV-to-EBITDA?
Genetics Generation AdvancementROCO:4160 -0.76%72 EV-to-EBITDA is 16.45 as of Sep. 04, 2026, which is 10% below its 10-year median of 18.19. GuruFocus rates ROCO:4160 with a GF Score™ of 72/100 and a GF Value™ of NT$53.29 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 122 Medical Diagnostics & Research companies, Genetics Generation Advancement ranks worse than 50.82% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Genetics Generation Advancement's enterprise value is NT$857.9 Mil.
Genetics Generation Advancement's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$52.2 Mil. Therefore, Genetics Generation Advancement's EV-to-EBITDA for today is 16.45.
The historical rank and industry rank for Genetics Generation Advancement's EV-to-EBITDA or its related term are showing as below:
ROCO:4160'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -1232.82 Med: 18.19 Max: 725.15
Current: 16.45
During the past 13 years, the highest EV-to-EBITDA of Genetics Generation Advancement was 725.15. The lowest was -1232.82. And the median was 18.19.
ROCO:4160's EV-to-EBITDA is ranked worse than 50.82% of 122
companies
in the Medical Diagnostics & Research industry
Industry Median: 16.23
vs ROCO:4160: 16.45
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Genetics Generation Advancement's PE Ratio (TTM) for today is calculated as:
Genetics Generation Advancement's share price for today is NT$39.40.
Genetics Generation Advancement's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.680.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4160 vs TMO, DHR, NTRA: EV-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Genetics Generation Advancement's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genetics Generation Advancement EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genetics Generation Advancement's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Genetics Generation Advancement's EV-to-EBITDA falls into.
Genetics Generation Advancement's current Enterprise Value is NT$857.9 Mil.
Genetics Generation Advancement's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$52.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genetics Generation Advancement (ROCO:4160) has a EV-to-EBITDA of 16.45 as of Sep. 04, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Genetics Generation Advancement. This is 10% below median its historical median of 18.19. According to the industry distribution chart, Genetics Generation Advancement ranks #62 out of 122 companies in the Medical Diagnostics & Research industry, placing it in the top 50.8%.
Is Genetics Generation Advancement's EV-to-EBITDA too high?
Genetics Generation Advancement's current EV-to-EBITDA of 16.45 is 10% below median its 10-year median of 18.19. The Medical Diagnostics & Research industry median EV-to-EBITDA is 16.23. Genetics Generation Advancement's value of 16.45 is 1.4% above this industry median. Based on the distribution chart, Genetics Generation Advancement ranks #62 out of 122 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Genetics Generation Advancement has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genetics Generation Advancement's EV-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Genetics Generation Advancement ranks #62 out of 122 companies for EV-to-EBITDA. This places Genetics Generation Advancement in the lower half of its industry. The industry median EV-to-EBITDA is 16.23. Genetics Generation Advancement's value of 16.45 is 1.4% above this benchmark. While the company's 10-year median is 18.19 vs. the industry median of 16.23, Genetics Generation Advancement has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 16.23, based on 122 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genetics Generation Advancement's current EV-to-EBITDA of 16.45 is 1.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Genetics Generation Advancement. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 16.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genetics Generation Advancement's current EV-to-EBITDA is 16.45, which is 10% below median its own 10-year median of 18.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetics Generation Advancement stock overvalued right now?
Based on GuruFocus' analysis, Genetics Generation Advancement (ROCO:4160) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$53.29, compared to a current price of NT$39.40 — trading 26.1% below its estimated fair value. The current EV-to-EBITDA is 16.45, which is 10% below median its 10-year median of 18.19 and 1.4% above the Medical Diagnostics & Research industry median of 16.23. Genetics Generation Advancement's overall GF Score™ is 72/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Genetics Generation Advancement (ROCO:4160), the current EV-to-EBITDA is 16.45 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genetics Generation Advancement (ROCO:4160) Overvalued in 2026?
Based on GuruFocus' analysis, Genetics Generation Advancement stock appears to be undervalued.
The current stock price of NT$39.40 is trading 26.1% below its estimated GF Value™ of NT$53.29.
GuruFocus considers Genetics Generation Advancement to be Modestly Undervalued.
Key valuation signals for ROCO:4160:
EV-to-EBITDA: 16.45 (10% below median its 10-year median of 18.19)
GF Value™: NT$53.29 vs. price of NT$39.40 (26.1% below fair value)
Industry Position: 1.4% above the Medical Diagnostics & Research median (#62 of 122)
No single metric tells the full story. See the ROCO:4160 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genetics Generation Advancement Corp is a Taiwan based company specialized in genetic testing and scientific information. It is engaged in providing services for the detection of genetic defects and prevention in newborns. Their main services include amniotic fluid chromosome chip screening, pre-implantation genetic diagnosis, and Molecular DNA testing diagnostics. The company is focused on the majority of areas of maternal precision medicine, pediatric disease diagnosis, drug-associated diagnosis, non-invasive cancer detection, and precise health management. The business units of the company are the Genetic Testing Unit and Informatics business unit.
72GF Score
Get the complete analysis for ROCO:4160
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4160 has been successfully added to your 
